We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH HEARS ARGUMENTS TO TURN ABBOTT'S AIDS DRUG GENERIC
NIH HEARS ARGUMENTS TO TURN ABBOTT'S AIDS DRUG GENERIC
June 1, 2004
Abbott Laboratories recently squared off with AIDS activists who want the government to break the patent on Abbott’s AIDS drug Norvir (ritonavir) and allow generic versions of the product. The controversy stems from Abbott’s decision in December to raise the price of Norvir by 400 percent — a move that Abbott argues reflects market value of the product.